Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.
about
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumorThe role of CD95 and CD95 ligand in cancerTwo-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice.Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progressionIonizing radiation as a response-enhancing agent for CD95-mediated apoptosis.Role of integrin CD103 in promoting destruction of renal allografts by CD8 T cells.T-cell-directed cancer vaccines: the melanoma model.T lymphocytes in host defense against bacterial translocation from the gastrointestinal tractTumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Adoptive-cell-transfer therapy for the treatment of patients with cancerB7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityA novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer.Tumor-specific T cells signal tumor destruction via the lymphotoxin beta receptorIn situ detection of activated cytotoxic cells in follicular lymphomas.B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumorMurine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivoCell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancerLysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitisHuman Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid miceCD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cellsOligoclonality of CD8+ T cells in breast cancer patients.Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms3,3'-Diindolylmethane stimulates murine immune function in vitro and in vivoMolecular alterations in pediatric sarcomas: potential targets for immunotherapyPhosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast canceAnti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
P2860
Q24312048-C01B3A2B-7B15-4998-B1E6-5E1308237AE4Q26995847-486E0208-0084-46AB-90B5-23566AD9DDA5Q30481516-9457537B-8971-4138-B61D-07A8EEFBDB05Q33418929-2013D35E-C277-4BAA-853E-134F32116FAFQ33804742-28B1CF20-375D-4ABD-8ADD-CA9B959C2041Q33905476-1A4C850F-4C85-4836-8504-52E81317EF62Q33929802-1695C569-9ECC-44C9-86BC-9C64498D7DC0Q34145881-5BD0CAEF-D4E1-408C-A7DE-DF18A7064A3EQ34168497-EA5610CF-412C-4D7B-B575-925DA700D005Q34320209-7F60CEBB-E39A-4B2F-8D28-B7F396FF7DD1Q34326860-96BF89E8-8E13-4A64-B965-216110EEC969Q34452071-9E84A49D-A6E2-48ED-886E-EF16B879D591Q34529990-E2E79045-AA4A-4651-88A4-3652EBB09BC3Q34823085-033E517A-CC59-4A18-A1FA-EB4C36831B4DQ35209066-35852FBE-9844-481F-93F4-5A7865703138Q35210008-625F14E7-C732-4FD3-A356-5CD32419E5A0Q35613233-71919CDF-7C9E-4B6A-87A5-7B7EC3DEE998Q35621559-40F6A304-BED1-455B-B863-89CD5D8A5A66Q35723152-0FA99681-659F-40F9-A40F-7C8E6F07FB5BQ35833276-C7FB290C-5B7B-4895-985D-28C1E128A67EQ35929030-AE1A5AA0-B2C5-4729-85F4-48109891697FQ35987503-55BBA120-D048-4B84-BA93-D603472D3E3BQ36198732-E17782F9-6D2A-43AC-9AC2-98E201E2B574Q36238339-04950B36-8C79-4862-8F78-448DA0041771Q36262520-AC520334-FE77-489F-B687-8BD863F468C2Q36303665-95CE7F7C-3C49-432B-8677-ACA46B18023DQ36361920-0135C204-9C64-48F7-88AD-5FDA1B4DDE91Q36362505-7DA6721A-A076-4D0C-8D0D-DFE9DBB8AFB3Q36365868-3313D286-022C-4603-A2B5-A41450D8CEAFQ36371171-E59FBDF0-D4A7-4E17-B2EE-BAEA7EC7A3FFQ36438149-074596B3-19EA-46CD-8AFF-82B88B0A7E63Q36453976-A420EB7B-48DE-43BF-834D-CC7E1EEFF184Q36470715-60D71745-D434-4BC4-9C21-F8F1161C2FDDQ36585688-D5775962-619C-4133-91F3-8B82960E382FQ36663538-6BDF921D-6074-41BC-A98B-A0F7219AC62BQ36673885-C92BA457-2B40-4CF0-A794-E15A3E59034DQ36895458-F1CCC04E-2328-48A3-BD2B-2126ABF20386Q36914397-24CD5840-8E7D-4B7D-934E-CB8822CD7155Q36914404-74B84E92-7511-4036-A73E-B3DA6C53FA1BQ37074414-21956287-F4A3-4422-98A9-56EC68A5CEB5
P2860
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@ast
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@en
type
label
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@ast
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@en
prefLabel
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@ast
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@en
P2093
P2860
P356
P1476
Interferon gamma and tumor nec ...... umor-infiltrating lymphocytes.
@en
P2093
Barth RJ Jr
Rosenberg SA
P2860
P304
P356
10.1084/JEM.173.3.647
P407
P577
1991-03-01T00:00:00Z